# Temporal trajectory of plasma miRNA during the peri-implantation stage: comparing implantation success and failure in single frozen–thawed blastocyst transfers

**Authors:** Lu Wang, Xiang Xiao, Hongya Yang, Ying Ju, Xiao He, Lingyin Kong, Shuqiang Chen, Xiuyu Feng, Jing Wu, Yue Liang, Yuan Ma, Juan Zhou, Bo Liang, Ni Jin, Jianlei Huang, Li Hai, Xiaohong Wang

PMC · DOI: 10.3389/fendo.2026.1708664 · Frontiers in Endocrinology · 2026-02-16

## TL;DR

This study tracks changes in plasma miRNA levels during early pregnancy to understand differences between successful and failed implantations.

## Contribution

The study identifies dynamic miRNA expression patterns and their clinical relevance in implantation success and failure.

## Key findings

- Twenty-four dynamically differentially expressed miRNAs showed five distinct temporal patterns.
- Six miRNAs were validated in an independent set, and an SVM model achieved high AUC values for predicting implantation outcomes.
- The miRNA hsa-miR-214-3p and its target gene CTNNB1 were confirmed to be functionally associated in implantation.

## Abstract

Implantation failure is the most common cause of pregnancy failure and is a major limiting factor in assisted reproduction. Plasma microRNA (miRNA) expression profiles show dynamic changes among individuals with successful implantation. However, the trajectory differences in plasma miRNA expression between women with implantation failure and success, as well as the potential role of those miRNAs, remain unclear.

This study included 84 women who underwent single frozen–thawed blastocyst transfer in a natural cycle. For each patient, longitudinal plasma samples across five time points throughout the peri-implantation period (day0/D3/D5/D7/D9) were collected and underwent miRNA sequencing. The failure group (n = 27) encountered complete implantation failure, while the success group (n = 57) achieved a live birth. Using trajectory analysis and fuzzy c-means clustering, we identified dynamically differentially expressed (DDE) miRNAs and their dynamic expression patterns (DEPs) in a screening set (n = 52) and validated findings in an independent validation set (n = 32). Clinical correlations, functional annotation, prediction model, and in vitro validation of prioritized miRNA–target interactions were systematically conducted.

Twenty-four DDE miRNAs (FDR < 0.05) exhibited five temporal patterns: recession (R), growth (G), D3-trough (T), multimodal (M), and D5-trough (T2). The success group predominantly showed M-pattern miRNAs (62.5%), while failures demonstrated pattern transitions (M → T/T2) and exclusive T-pattern expression. Clinical relevance revealed eight DDE miRNAs associated with at least one clinical variable, with the majority being associated with estradiol/progesterone levels. Functional enrichment implicated Wnt/mTOR pathways in embryo implantation and decidualization. Six DDE miRNAs were successfully replicated in the validation set, while the support vector machine (SVM) model achieved area under the curve (AUC) values of 0.816 (D0) and 0.870 (D3). Additionally, the association between hsa-miR-214-3p and its target gene CTNNB1 was further confirmed in Ishikawa cells.

Understanding the dynamic landscape changes of the miRNA transcriptome in individuals with implantation failure will help identify dynamic biomarkers from ovulation to the post-implantation stage, providing new insights into the pathological mechanisms of implantation failure and facilitating the research and development of new therapies in the clinical setting.

## Linked entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499]

## Full-text entities

- **Genes:** MIR34C (microRNA 34c) [NCBI Gene 407042] {aka MIRN34C, miRNA34C, mir-34c}, IL11 (interleukin 11) [NCBI Gene 3589] {aka AGIF, IL-11}, MIR149 (microRNA 149) [NCBI Gene 406941] {aka MIRN149, mir-149}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, MIR31 (microRNA 31) [NCBI Gene 407035] {aka MIRN31, hsa-mir-31, miR-31}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, MIR1260A (microRNA 1260a) [NCBI Gene 100302236] {aka MIR1260, MIRN1260, hsa-mir-1260, hsa-mir-1260a, mir-1260a}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR299 (microRNA 299) [NCBI Gene 407023] {aka MIRN299, mir-299}, MIR665 (microRNA 665) [NCBI Gene 100126315] {aka MIRN665, hsa-mir-665, mir-665}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, WNT7A (Wnt family member 7A) [NCBI Gene 7476] {aka SANTOS, Wnt-7a}, LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976] {aka CDF, DIA, HILDA, MLPLI}, MIR122 (microRNA 122) [NCBI Gene 406906] {aka MIR122A, MIRN122, MIRN122A, hsa-mir-122, miRNA122, miRNA122A}, MIR1323 (microRNA 1323) [NCBI Gene 100302255] {aka MIRN1323, hsa-mir-1323, mir-1323}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, MIR5683 (microRNA 5683) [NCBI Gene 100847034], IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PARP2 (poly(ADP-ribose) polymerase 2) [NCBI Gene 10038] {aka ADPRT2, ADPRTL2, ADPRTL3, ARTD2, PARP-2, pADPRT-2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MIR1343 (microRNA 1343) [NCBI Gene 100616437], hsa-miR-127-3p [NCBI Gene 100302165], AMH (anti-Mullerian hormone) [NCBI Gene 268] {aka MIF, MIS}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, ERVK-25 (endogenous retrovirus group K member 25) [NCBI Gene 100862683] {aka PR, Protease, Proteinase, c11_A}
- **Diseases:** tubal or male factor infertility (MESH:D007248), hepatocellular carcinoma (MESH:D006528), hypoxia (MESH:D000860), autoimmune diseases (MESH:D001327), pregnancy loss (MESH:D000022), WOI (MESH:D057873), uterine abnormalities (MESH:D014591), adenomyosis (MESH:D062788), thyroid disorders (MESH:D013959), hyperprolactinemia (MESH:D006966), progesterone resistance (MESH:C564871), infertility (MESH:D007246), pregnancy failure (MESH:D051437), endometriosis (MESH:D004715), DDE (MESH:D001039), endometrial carcinoma (MESH:D016889), intrauterine adhesions (MESH:D000267)
- **Chemicals:** sodium dodecyl sulfate (MESH:D012967), PVDF (MESH:C024865), progesterone (MESH:D011374), Tween-20 (MESH:D011136), glycine (MESH:D005998), CO2 (MESH:D002245), L-glutamine (MESH:D005973), water (MESH:D014867), TRIzol (MESH:C411644), TB (MESH:D013725), lipids (MESH:D008055), EDTA (MESH:D004492), E2 (MESH:D004958), Lipofectamine 2000 (MESH:C086724), saline (MESH:D012965), Dulbecco's modified Eagle's medium (-), HEPES (MESH:D006531), P (MESH:D010758)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Legionella sp. H (species) [taxon 66966], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955]
- **Cell lines:** Ishikawa — Homo sapiens (Human), Type I endometrial adenocarcinoma, Cancer cell line (CVCL_2529)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950558/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950558/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950558/full.md

---
Source: https://tomesphere.com/paper/PMC12950558